Published in Clin Cancer Res on August 01, 2007
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol (2009) 1.89
Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 1.79
Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 1.69
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
The development and function of regulatory T cells. Cell Mol Life Sci (2009) 1.66
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Immune responses to malignancies. J Allergy Clin Immunol (2010) 1.48
A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One (2009) 1.45
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 1.38
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Immune suppression in head and neck cancers: a review. Clin Dev Immunol (2011) 1.17
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16
Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol (2014) 1.13
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13
NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol (2009) 1.12
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front Oncol (2014) 1.11
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res (2015) 1.11
Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol (2015) 1.10
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. Laryngoscope (2012) 1.09
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 1.09
Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol (2009) 1.09
TGF-beta and tumors--an ill-fated alliance. Curr Opin Immunol (2008) 1.08
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS (2010) 1.03
Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog (2011) 1.02
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97
Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) (2010) 0.97
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology (2012) 0.96
Immune system: a double-edged sword in cancer. Inflamm Res (2013) 0.95
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
Regulatory T cell: a protection for tumour cells. J Cell Mol Med (2012) 0.91
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) (2015) 0.90
Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. PLoS One (2012) 0.90
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol (2010) 0.90
Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. PLoS One (2013) 0.89
T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol (2010) 0.89
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation. Expert Opin Biol Ther (2011) 0.89
Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res (2015) 0.89
Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin Immunol (2007) 0.88
CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer. Gastric Cancer (2011) 0.87
Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol (2014) 0.87
The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther (2014) 0.86
CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One (2014) 0.86
In vitro chemosensitivity of head and neck cancer cell lines. Eur J Med Res (2010) 0.84
Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol (2014) 0.84
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother (2014) 0.84
Immunological significance of the accumulation of autophagy components in oral squamous cell carcinoma. Cancer Sci (2014) 0.84
Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Clin Dev Immunol (2011) 0.83
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82
Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity. Cancer Immunol Immunother (2011) 0.82
Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate. Hum Reprod (2012) 0.82
NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay. Cancer Res (2015) 0.81
The effect of transforming growth factor-beta1 on nasopharyngeal carcinoma cells: insensitive to cell growth but functional to TGF-beta/Smad pathway. J Exp Clin Cancer Res (2010) 0.81
Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res (2009) 0.81
Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81
Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma. Contemp Oncol (Pozn) (2013) 0.81
Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Cancer Res (2015) 0.80
Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget (2016) 0.80
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology (2012) 0.80
Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis. PLoS One (2014) 0.80
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology (2014) 0.80
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. Front Immunol (2012) 0.80
Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J Transl Med (2016) 0.79
Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol (2013) 0.79
Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med Chem (2010) 0.78
Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 0.78
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we? Eur Arch Otorhinolaryngol (2015) 0.78
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. Biomedicines (2016) 0.77
Distinct different sensitivity of Treg and Th17 cells to Fas-mediated apoptosis signaling in patients with acute coronary syndrome. Int J Clin Exp Pathol (2013) 0.77
Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther (2015) 0.77
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J Biomed Biotechnol (2011) 0.77
Accumulation Mechanisms of CD4(+)CD25(+)FOXP3(+) Regulatory T Cells in EBV-associated Gastric Carcinoma. Sci Rep (2015) 0.76
Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oral Health Rep (2016) 0.76
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. Oncoimmunology (2017) 0.75
Radiochemotherapy fosters a favorable pattern of inflammatory cells in head and neck tumors. Oncoimmunology (2012) 0.75
Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS One (2016) 0.75
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol (2016) 0.75
TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. Oncotarget (2016) 0.75
INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts. BMC Cancer (2016) 0.75
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res (2005) 2.97
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Outcomes after nasal septoplasty: results from the Nasal Obstruction Septoplasty Effectiveness (NOSE) study. Otolaryngol Head Neck Surg (2004) 2.03
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res (2006) 1.91
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol (2009) 1.79
T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res (2003) 1.79
Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res (2005) 1.73
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
Cervical metastasis from squamous cell carcinoma of the maxillary alveolus and hard palate. Laryngoscope (2006) 1.68
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res (2007) 1.61
Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology (2005) 1.59
Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A (2005) 1.57
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods (2012) 1.46
Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res (2002) 1.45
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res (2003) 1.43
Publication misrepresentation among otolaryngology residency applicants. Otolaryngol Head Neck Surg (2010) 1.41
Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res (2007) 1.40
Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother (2003) 1.40
Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol (2002) 1.38
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Letter to the editor: impact of prophylactice percutaneous endoscopic gasatrostomy on malnutrition and QOL in patients with head and neck cancer: a randomized study. Head Neck (2012) 1.37
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res (2009) 1.37
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica (2011) 1.37
Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer (2005) 1.36
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One (2010) 1.32
Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res (2004) 1.32
Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother (2007) 1.30
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol (2002) 1.28
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res (2005) 1.27
A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery. Laryngoscope (2012) 1.26
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck (2009) 1.25
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother (2005) 1.25
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol (2008) 1.25
Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res (2002) 1.24
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol (2012) 1.21
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res (2010) 1.20
The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol (2006) 1.20
Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst (2008) 1.19
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys (2009) 1.17
Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope (2007) 1.17
Squamous cell carcinoma of the parotid gland. Head Neck (2006) 1.17
Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer (2011) 1.17
Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol (2002) 1.17
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol (2003) 1.16
Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer (2008) 1.15
Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods (2011) 1.15
Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother (2010) 1.15
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med (2007) 1.15
Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother (2008) 1.14
Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope (2010) 1.14
Neck dissection: then and now. Auris Nasus Larynx (2006) 1.14
Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol (2003) 1.14
Management of salivary flow in head and neck cancer patients--a systematic review. Oral Oncol (2008) 1.13